DC
Decheng Capital Portfolio holdings
AUM
$396M
This Quarter Return
-9.88%
1 Year Return
-5.21%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$466M
AUM Growth
+$466M
(+10%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
22.52%
Top 10 Holdings %
Top 10 Hldgs %
83.67%
Holding
30
New
4
Increased
10
Reduced
5
Closed
2
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$54M |
| 2 |
CG Oncology
CGON
|
$25.6M |
| 3 |
Revolution Medicines
RVMD
|
$9.8M |
| 4 |
Lyell Immunopharma
LYEL
|
$7.62M |
| 5 |
Aclaris Therapeutics
ACRS
|
$5.62M |
Top Sells
| 1 |
Phathom Pharmaceuticals
PHAT
|
$4.51M |
| 2 |
GeneDx Holdings
WGS
|
$4.4M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
$2.33M |
| 4 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$1.88M |
| 5 |
Arcus Biosciences
RCUS
|
$908K |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pyxis Oncology
PYXS
$79.4M
| $510K | 0.11% | 326,810 | – | – |
|
|
GRAL
27
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $173K | 0.04% | 9,684 | – | – |
|
28
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$68M
| $149K | 0.03% | 646,057 | – | – |
|
|
29
GeneDx Holdings
WGS
$3.72B
| – | – | -103,604 | Closed | -$4.4M |
|
|
LBPH
30
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – | -56,350 | Closed | -$1.88M |
|